Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent...
Barchart Research What to Expect from AVBP Earnings AVBP Generated May 8, 2026 Current Price $29.50 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 4.37% ArriVent BioPharma's Phase Three...
Barchart Research What to Expect from AVBP Earnings AVBP Generated May 8, 2026 Current Price $29.50 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 4.37% ArriVent BioPharma's Phase Three...
Barchart Research What to Expect from AVBP Earnings AVBP Generated May 8, 2026 Current Price $29.50 EPS Estimate $$-0.88 Consensus Rating Strong Buy Average Move 4.37% ArriVent BioPharma's Phase Three...
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026...
Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models Superior anti-tumor activity...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to support...
Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17...
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative...